Our verdict is Benign. Variant got -16 ACMG points: 4P and 20B. PM1PM5BP4_StrongBP6_Very_StrongBS1BS2
The NM_000548.5(TSC2):āc.5017G>Cā(p.Val1673Leu) variant causes a missense change. The variant allele was found at a frequency of 0.000221 in 1,612,026 control chromosomes in the GnomAD database, including 6 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V1673D) has been classified as Pathogenic.
TSC2 (HGNC:12363): (TSC complex subunit 2) This gene is a tumor suppressor gene that encodes the growth inhibitory protein tuberin. Tuberin interacts with hamartin to form the TSC protein complex which functions in the control of cell growth. This TSC protein complex negatively regulates mammalian target of rapamycin complex 1 (mTORC1) signaling which is a major regulator of anabolic cell growth. Mutations in this gene have been associated with tuberous sclerosis and lymphangioleiomyomatosis. [provided by RefSeq, May 2022]
In a domain Rap-GAP (size 227) in uniprot entity TSC2_HUMAN there are 284 pathogenic changes around while only 47 benign (86%) in NM_000548.5
PM5
Other missense variant is known to change same aminoacid residue: Variant chr16-2087891-T-A is described in Lovd as [Pathogenic].
BP4
Computational evidence support a benign effect (MetaRNN=0.0126879215).
BP6
Variant 16-2087890-G-C is Benign according to our data. Variant chr16-2087890-G-C is described in ClinVar as [Likely_benign]. Clinvar id is 49495.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr16-2087890-G-C is described in Lovd as [Benign].
BS1
Variant frequency is greater than expected in population sas. gnomad4_exome allele frequency = 0.000234 (342/1460060) while in subpopulation SAS AF= 0.00384 (331/86244). AF 95% confidence interval is 0.0035. There are 6 homozygotes in gnomad4_exome. There are 222 alleles in male gnomad4_exome subpopulation. Median coverage is 32. This position pass quality control queck.
Likely benign, criteria provided, single submitter
clinical testing
Myriad Genetics, Inc.
Aug 06, 2024
This variant is considered likely benign. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. -
not provided Benign:2
Benign, criteria provided, single submitter
clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano
Feb 11, 2022
- -
Benign, criteria provided, single submitter
clinical testing
GeneDx
Feb 15, 2021
This variant is associated with the following publications: (PMID: 24728327, 15595939, 28991257) -
Hereditary cancer-predisposing syndrome Benign:2
Benign, criteria provided, single submitter
clinical testing
Ambry Genetics
Jul 08, 2016
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Likely benign, criteria provided, single submitter
curation
Sema4, Sema4
Jul 13, 2021
- -
TSC2-related disorder Benign:1
Benign, no assertion criteria provided
clinical testing
PreventionGenetics, part of Exact Sciences
Sep 15, 2020
This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -